A new look at managing hyperkalemia in high-risk patients. Issue 3 (May 2020)

• Record Type: Journal Article
• Authors: Earl, Grace
• Is Part Of: Nursing ... critical care. Volume 15:Issue 3(2020)
• Publication Date: 2020-05
• Subjects: chronic kidney disease (CKD) -- hyperkalemia -- patiromer -- potassium binder -- renin-angiotensin-aldosterone system (RAAS) -- sodium zirconium cyclosilicate (SZC); Intensive care nursing -- Periodicals; Intensive care nursing -- United States -- Periodicals; Critical care medicine -- Periodicals; 616.028
• DOI: 10.1097/01.CCN.0000660380.54808.53
• Languages: English
• ISSNs: 1558-447X

Abstract

Abstract : Abstract: Two medications that bind potassium in the gastrointestinal (GI) tract are indicated for hyperkalemia management. Patiromer and sodium zirconium cyclosilicate have been studied in patients with chronic kidney disease, diabetes, and heart failure. Recent studies have examined the role of potassium binders as maintenance therapy to control hyperkalemia in high-risk patients. This strategy has an added advantage of allowing continuation of concomitant medications affecting the renin-angiotensin-aldosterone system. These medications are generally well tolerated but may cause GI symptoms and hypomagnesemia. Abstract : Two medications that bind potassium in the gastrointestinal tract are indicated for hyperkalemia management. Patiromer and sodium zirconium cyclosilicate have been studied in patients with chronic kidney disease, diabetes, and heart failure. Recent studies have examined the role of potassium binders as maintenance therapy to control hyperkalemia in high-risk patients.